PEB Stock Overview
A cancer diagnostics company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Pacific Edge Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NZ$0.12 |
52 Week High | NZ$0.18 |
52 Week Low | NZ$0.08 |
Beta | 1.06 |
1 Month Change | -15.71% |
3 Month Change | -31.40% |
1 Year Change | 28.26% |
3 Year Change | -90.99% |
5 Year Change | -1.67% |
Change since IPO | -32.57% |
Recent News & Updates
It's Down 26% But Pacific Edge Limited (NZSE:PEB) Could Be Riskier Than It Looks
Dec 10Is Pacific Edge (NZSE:PEB) In A Good Position To Invest In Growth?
Nov 15Recent updates
It's Down 26% But Pacific Edge Limited (NZSE:PEB) Could Be Riskier Than It Looks
Dec 10Is Pacific Edge (NZSE:PEB) In A Good Position To Invest In Growth?
Nov 15Further Upside For Pacific Edge Limited (NZSE:PEB) Shares Could Introduce Price Risks After 33% Bounce
Sep 16Here's Why We're Watching Pacific Edge's (NZSE:PEB) Cash Burn Situation
Aug 16Investors Holding Back On Pacific Edge Limited (NZSE:PEB)
Apr 30Here's Why We're Watching Pacific Edge's (NZSE:PEB) Cash Burn Situation
Feb 19Lacklustre Performance Is Driving Pacific Edge Limited's (NZSE:PEB) 30% Price Drop
Dec 18Fewer Investors Than Expected Jumping On Pacific Edge Limited (NZSE:PEB)
Jun 06Pacific Edge Limited (NZSE:PEB) Annual Results: Here's What Analysts Are Forecasting For This Year
May 27We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely
May 23Companies Like Pacific Edge (NZSE:PEB) Are In A Position To Invest In Growth
Sep 06Pacific Edge (NZSE:PEB) Is In A Good Position To Deliver On Growth Plans
May 31Pacific Edge (NZSE:PEB) Is In A Strong Position To Grow Its Business
Jan 17We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely
Jun 05Pacific Edge Limited (NZSE:PEB): Are Analysts Optimistic?
May 14Don't Ignore The Fact That This Insider Just Sold Some Shares In Pacific Edge Limited (NZSE:PEB)
Mar 21Did The Underlying Business Drive Pacific Edge's (NZSE:PEB) Lovely 750% Share Price Gain?
Mar 13Have Insiders Been Selling Pacific Edge Limited (NZSE:PEB) Shares?
Feb 14Pacific Edge Limited's (NZSE:PEB) Profit Outlook
Jan 18How Much Of Pacific Edge Limited (NZSE:PEB) Do Insiders Own?
Dec 23Did You Participate In Any Of Pacific Edge's (NZSE:PEB) Incredible 434% Return?
Nov 21Shareholder Returns
PEB | NZ Biotechs | NZ Market | |
---|---|---|---|
7D | 1.7% | 0.1% | 1.2% |
1Y | 28.3% | 3.1% | 6.1% |
Return vs Industry: PEB exceeded the NZ Biotechs industry which returned 3.1% over the past year.
Return vs Market: PEB exceeded the NZ Market which returned 6.1% over the past year.
Price Volatility
PEB volatility | |
---|---|
PEB Average Weekly Movement | 10.0% |
Biotechs Industry Average Movement | 9.9% |
Market Average Movement | 4.6% |
10% most volatile stocks in NZ Market | 9.1% |
10% least volatile stocks in NZ Market | 3.1% |
Stable Share Price: PEB's share price has been volatile over the past 3 months compared to the NZ market.
Volatility Over Time: PEB's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of NZ stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 114 | Peter Meintjes | www.pacificedgedx.com |
Pacific Edge Limited, a cancer diagnostics company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer.
Pacific Edge Limited Fundamentals Summary
PEB fundamental statistics | |
---|---|
Market cap | NZ$95.81m |
Earnings (TTM) | -NZ$28.79m |
Revenue (TTM) | NZ$22.62m |
4.2x
P/S Ratio-3.3x
P/E RatioIs PEB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PEB income statement (TTM) | |
---|---|
Revenue | NZ$22.62m |
Cost of Revenue | NZ$11.57m |
Gross Profit | NZ$11.05m |
Other Expenses | NZ$39.84m |
Earnings | -NZ$28.79m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.035 |
Gross Margin | 48.86% |
Net Profit Margin | -127.26% |
Debt/Equity Ratio | 0.7% |
How did PEB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 05:59 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pacific Edge Limited is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Anubhav Saxena | Bell Potter |
null null | Brookline Capital Markets |
Gregory Main | Credit Suisse |